GRAIL
GRAIL is revolutionizing cancer detection through innovative technology and data science, aiming to enable early diagnosis and improve patient outcomes. The company collaborates with a multidisciplinary team to advance cancer detection methods using next-generation sequencing and large-scale clinical studies.
Headquarters
Menlo Park, California, United States
Company Size
1001-5000 employees
Founded
2016
GRAIL, LLC is a healthcare company focused on detecting cancer early, when it can be cured. It develops blood-based multi‑cancer early detection tests (notably the Galleri test) that use high‑intensity sequencing of cell‑free DNA methylation patterns and machine learning to identify cancer signals across many tumor types. GRAIL partners with clinicians, health systems, and researchers to bring earlier diagnosis and population‑level screening into clinical practice.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for GRAIL.
GRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026
5 hours ago
Statistical Research Associate II
Fred Hutchinson Cancer Center
Statistical Science Director - Early Oncology
AstraZeneca
Senior Staff Clinical Data Manager
DELFI Diagnostics, Inc.
Biostatistician I
University of Southern California
Post-Doctoral Research Fellow
Fred Hutchinson Cancer Center
Statistical Scientist, Oncology (Biostatistics)
Astellas